China, Merck and HPV
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Fierce Pharma Asia—A $410M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
The stock's fall snapped a two-day winning streak.
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).
Doctors may change how they treat liver cancer after drugs from AstraZeneca Plc and Merck & Co. helped some patients, marking ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best low volatility stocks to buy right now. The market has shown strong performance overall ...
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...
Hosted on MSN6h
What to Expect From Merck & Co.'s Q4 2024 Earnings ReportWith a market cap of $252.6 billion, Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global leader in the healthcare ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback